Hertz, Daniel L.
Dockter, Travis J.
Satele, Daniel V.
Loprinzi, Charles L.
Le-Rademacher, Jennifer
Funding for this research was provided by:
National Institutes of Health (UG1CA189823, UG1CA232760)
Article History
Received: 5 March 2021
Accepted: 17 June 2021
First Online: 27 June 2021
Declarations
:
: The authors have no relevant employment to disclose. The authors have declared all relevant financial interests including consulting fees from PledPharma, Disarm Therapeutics, Asahi Kasei, Metys Pharmaceuticals, NKMax, Novartis, HengRui, Nruo Bio, Osmol Therapeutics Inc, and Grunenthal to Dr. Loprinzi for research related to chemotherapy-induced peripheral neuropathy. The authors have also received funding from the Alliance for Clinical Trials in Oncology (ACTION) for travel related to attending meetings.
: The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: All patients provided written IRB-approved, protocol-specific informed consent to participate, in accordance with federal and institutional guidelines.
: All patients provided written IRB-approved, protocol-specific informed consent to participate, in accordance with federal and institutional guidelines.